| Literature DB >> 33708954 |
Chifa Ma1, Yiwen Liu1, Shuli He2, Jingbo Zeng3, Pingping Li4,5, Chunxiao Ma4,5, Fan Ping1, Huabing Zhang1, Lingling Xu1, Wei Li1, Yuxiu Li1.
Abstract
BACKGROUNDS: Glucose fluctuation (GF) may have detrimental effects in individuals with diabetes; however, clinical data on the association between short-term GF, inflammation/oxidative stress markers, and islet β-cell function based on a population with normal glucose tolerance (NGT) are insufficient. Therefore, we aimed to explore these associations in a Chinese population of 209 individuals with NGT in a cross-sectional analysis.Entities:
Keywords: glucose fluctuation; inflammation; oxidative stress; β-cell function
Year: 2021 PMID: 33708954 PMCID: PMC7944279 DOI: 10.21037/atm-20-6119
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1The flow chart of the population-based study.
Association of glucose fluctuation with Clinical and demographic characteristics
| Lowest GF (n=69) | Middle GF (n=71) | Highest GF (n=69) | P | |
|---|---|---|---|---|
| GF (mmol/L) | 2.37 (1.54–2.80) | 4.07 (3.76–4.49)* | 5.96 (5.34–7.38)*# | <0.001 |
| Gender, n (%) | <0.001 | |||
| Female | 56 (81.2) | 56 (78.9) | 33 (47.8) | |
| Male | 13 (18.8) | 15 (21.1) | 36 (52.2) | |
| Age (years) | 46.42±10.87 | 50.08±11.1 | 53.55±10.72* | 0.001 |
| BMI (kg/m2) | 24.87±3.46 | 25.72±3.65 | 25.44±3.6 | 0.356 |
| SBP (mmHg) | 121.06±16.98 | 126.96±17.96 | 126.96±17.24 | 0.073 |
| DBP (mmHg) | 76.49±9.64 | 75.82±10.32 | 74.87±9.31 | 0.619 |
| TC (mmol/L) | 5.13±0.95 | 5.40±1.19 | 5.39±0.91 | 0.215 |
| LnTG (mmol/L) | 0.14±0.50 | 0.25±0.55 | 0.26±0.55 | 0.304 |
| HDL-C (mmol/L) | 1.35±0.54 | 1.35±0.28 | 1.29±0.27 | 0.542 |
| LDL-C (mmol/L) | 2.58±0.72 | 2.78±0.78 | 2.79±0.66 | 0.179 |
| UA (umol/L) | 262.64±74.09 | 282.33±79.62 | 298.82±75.75* | 0.023 |
| HbA1c (%) | 5.2 (5.0–5.5) | 5.4 (5.2–5.6) | 5.5 (5.15–5.7)* | 0.009 |
| FPG (mmol/L) | 5.42 (5.13–5.65) | 5.57 (5.37–5.76) | 5.43 (5.26–5.80) | 0.081 |
| 2h-PPG (mmol/L) | 6.11 (5.11–6.83) | 6.28 (5.69–7.15) | 5.90 (4.62–6.83) | 0.054 |
| LnHOMA-IR | 0.77±0.43 | 0.84±0.47 | 0.71±0.67 | 0.353 |
| Ln (ISIM) | 1.59±0.42 | 1.43±0.46 | 1.42±0.64 | 0.105 |
| DI30 | 229.89±82.97 | 174.12±45.55* | 151.77±70.92* | <0.001 |
| DI120 | 226.24±67.03 | 212.11±42.47* | 209.07±62.12* | <0.001 |
| TNF-α (fmol/mL) (n=174) | 19.70 (14.45–25.06) | 27.83 (18.45–35.50)* | 25.75 (18.98–34.53)* | <0.001 |
| IL-6 (pg/mL) (n=173) | 3.05 (1.98–4.90) | 3.73 (2.48–4.48) | 3.53 (2.11–5.55) | 0.651 |
| 8-oxo-dG (pg/mL) (n=173) | 36.63 (23.09–53.40) | 36.63 (20.73–56.03) | 43.81 (26.46–63.56) | 0.324 |
| SOD (U/mL) (n=174) | 56.41 (45.63–66.08) | 60.16 (53.47–70.13) | 62.52 (55.34–75.12)* | 0.030 |
Data were presented as mean ± SD, n (%) or median (interquartile range). *Compared with the lowest tertile of GF, a two-side P<0.05 was considered statistically significant; #Compared with the middle tertile of GF, a two-side P<0.05 was considered statistically significant. GF, glucose fluctuation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; UA, uric acid; HbA1c, hemoglobin A1c; FPG, fasting plasma glucose; PPG, postprandial plasma glucose; HOMA-IR, homeostatic model assessment of insulin resistance; ISIM, Matsuda insulin sensitivity index; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; 8-oxo-dG, 8-oxo-2'-deoxyguanosine; SOD, superoxide dismutase.
Correlations of glucose fluctuation, inflammation and oxidative stress markers, and β-cell function and insulin sensitivity index
| DI30 | DI120 | LnHOMA-IR | LnISIM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| r | P | r | P | r | P | r | P | ||||
| GF (n=209) | −0.493 | <0.001 | −0.431 | <0.001 | −0.032 | 0.643 | −0.134 | 0.052 | |||
| TNF-α (n=174) | −0.136 | 0.073 | −0.183 | 0.016 | −0.086 | 0.260 | 0.008 | 0.912 | |||
| IL-6 (n=173) | −0.152 | 0.046 | −0.210 | 0.005 | 0.025 | 0.746 | 0.027 | 0.725 | |||
| 8-oxo-dG (n=173) | −0.152 | 0.046 | −0.072 | 0.346 | −0.027 | 0.720 | 0.029 | 0.709 | |||
| SOD (n=174) | −0.109 | 0.153 | −0.187 | 0.014 | −0.097 | 0.205 | 0.024 | 0.756 | |||
A two-side P<0.05 was considered statistically significant. HOMA-IR, homeostatic model assessment of insulin resistance; ISIM, Matsuda insulin sensitivity index; GF, glucose fluctuation; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; 8-oxo-dG, 8-oxo-2'-deoxyguanosine; SOD, superoxide dismutase.
β coefficients and 95% confidence intervals of multiple linear regression models of glucose fluctuation with β-cell function
| DI30 | DI120 | ||||
|---|---|---|---|---|---|
| β (95% CI) | P | β (95% CI) | P | ||
| Model 1 | −29.818 (−39.519, −20.118) | <0.001 | −20.676 (−28.870, −12.482) | <0.001 | |
| Model 2 | −30.006 (−39.653, −20.359) | <0.001 | −20.347 (−28.550, −12.144) | <0.001 | |
| Model 3 | −35.964 (−44.814, −27.115) | <0.001 | −26.205 (−33.418, −18.991) | <0.001 | |
Model 1 was adjusted for age, gender, body mass index and systolic blood pressure. Model 2 was adjusted for the covariates of model 1 plus triglycerides, high-density lipoprotein cholesterol and uric acid. Model 3 was adjusted for the covariates of model 2 plus 2-hour postprandial plasma glucose. A two-side P<0.05 was considered statistically significant. β coefficients and 95% confidence intervals (CI) were calculated as per 1-SD increment of glucose fluctuation.
β coefficients and 95% confidence intervals of multiple linear regression models of glucose fluctuation with inflammation markers
| TNF-α (n=174) | IL-6 (n=173) | ||||
|---|---|---|---|---|---|
| β (95% CI) | P | β (95% CI) | P | ||
| Model 1 | 2.204 (0.719, 3.689) | 0.004 | 0.292 (−0.215, 0.799) | 0.257 | |
| Model 2 | 2.143 (0.650, 3.636) | 0.005 | 0.254 (−0.254, 0.762) | 0.325 | |
| Model 3 | 2.314 (0.786, 3.842) | 0.003 | 0.253 (−0.268, 0.774) | 0.339 | |
TNF-α, tumor necrosis factor-α; IL-6, interleukin-6. Model1 was adjusted for age, gender, body mass index and systolic blood pressure. Model 2 was adjusted for the covariates of model 1 plus triglycerides, high-density lipoprotein cholesterol and uric acid. Model 3 was adjusted for the covariates of model 2 plus 2-hour postprandial plasma glucose. A two-side P<0.05 was considered statistically significant. β coefficients and 95% confidence intervals (CI) were calculated as per 1-SD increment of glucose fluctuation.
β coefficients and 95% confidence intervals of multiple linear regression models of glucose fluctuation with oxidative stress markers
| 8-oxo-dG (n=173) | SOD (n=174) | ||||
|---|---|---|---|---|---|
| β (95% CI) | P | β (95% CI) | P | ||
| Model 1 | 6.240 (0.835, 11.646) | 0.024 | 4.178 (1.341, 7.105) | 0.004 | |
| Model 2 | 6.057 (0.652, 11.461) | 0.028 | 4.082 (1.237, 6.927) | 0.005 | |
| Model 3 | 5.654 (0.140, 11.167) | 0.045 | 4.564 (1.662, 7.467) | 0.002 | |
8-oxo-dG, 8-oxo-2'-deoxyguanosine; SOD, superoxide dismutase Model 1 was adjusted for age, gender, body mass index and systolic blood pressure. Model 2 was adjusted for the covariates of model 1 plus triglycerides, high-density lipoprotein cholesterol and uric acid. Model 3 was adjusted for the covariates of model 2 plus 2-hour postprandial plasma glucose. A two-side P<0.05 was considered statistically significant. β coefficients and 95% confidence intervals (CI) were calculated as per 1-SD increment of glucose fluctuation.
β coefficients and 95% confidence intervals of multiple linear regression models of inflammation and oxidative stress markers with β-cell function
| DI30 | DI120 | ||||
|---|---|---|---|---|---|
| β (95% CI) | P | β (95% CI) | P | ||
| TNF-α (n=174) | |||||
| Model 1 | −5.574 (−16.573, 5.424) | 0.318 | −9.455 (−17.895, −1.015) | 0.028 | |
| Model 2 | −6.520 (−17.597, 4.558) | 0.247 | −9.245 (−17.683, −0.807) | 0.032 | |
| Model 3 | −5.831 (−16.395, 4.733) | 0.277 | −8.612 (−16.459, −0.766) | 0.032 | |
| IL-6 (n=173) | |||||
| Model 1 | −10.933 (−21.812, −0.053) | 0.049 | −11.672 (−20.025, −3.319) | 0.006 | |
| Model 2 | −11.333 (−22.339, −0.327) | 0.044 | −10.669 (−19.080, −2.258) | 0.013 | |
| Model 3 | −11.732 (−22.172, −1.292) | 0.028 | −11.038 (−18.796, −3.279) | 0.006 | |
| 8-oxo-dG (n=173) | |||||
| Model 1 | −10.407 (−21.393, 0.580) | 0.063 | −6.439 (−15.352, 2.474) | 0.156 | |
| Model 2 | −9.137 (−20.322, 2.048) | 0.109 | −5.127 (−14.079, 3.826) | 0.260 | |
| Model 3 | −11.269 (−21.917, −0.620) | 0.038 | −7.355 (−15.512, 0.803) | 0.077 | |
| SOD (n=174) | |||||
| Model 1 | −9.276 (−20.175, 1.623) | 0.095 | −9.891 (−18.164, −1.618) | 0.019 | |
| Model 2 | −8.529 (−19.569, 2.510) | 0.129 | −9.240 (−17.543, −0.936) | 0.029 | |
| Model 3 | −7.079 (−17.651, 3.492) | 0.188 | −7.897 (−15.636, −0.158) | 0.046 | |
TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; 8-oxo-2'-deoxyguanosine; SOD, superoxide dismutase Model 1 was adjusted for age, gender, body mass index and systolic blood pressure. Model 2 was adjusted for the covariates of model 1 plus triglycerides, high-density lipoprotein cholesterol and uric acid. Model 3 was adjusted for the covariates of model 2 plus 2-hour postprandial plasma glucose. A two-side P<0.05 was considered statistically significant. β coefficients and 95% confidence intervals (CI) were calculated as per 1-SD increment of inflammation and oxidative stress markers.